[PD-1抑制剂联合来那度胺治疗复发CD5弥漫大B细胞淋巴瘤的临床分析]
[Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5 Diffuse Large B-Cell Lymphoma].
作者信息
Wang Ya-Ping, Zhang Xue-Ya
机构信息
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Aug;32(4):1112-1116. doi: 10.19746/j.cnki.issn.1009-2137.2024.04.021.
OBJECTIVE
To investigate the clinical characteristics and treatment of relapsed CD5 diffuse large B-cell lymphoma (DLBCL).
METHODS
The data of a patient with CD5 DLBCL was collected, and its clinical characteristics and treatment outcome were analyzed.
RESULTS
The patient developed hemophagocytic syndrome and achieved complete remission (CR) after 6 cycles of R-ECHOP chemotherapy, then relapsed. After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment, the patient achieved CR again accompanied by a decrease of interleukin (IL)-10 expression level. After a total of 15 cycles of chemotherapy, the patient remained in CR for 24 months, and the level of IL-10 remained in the normal range.
CONCLUSION
PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5 DLBCL.
目的
探讨复发的CD5弥漫性大B细胞淋巴瘤（DLBCL）的临床特征及治疗方法。
方法
收集1例CD5 DLBCL患者的数据，分析其临床特征及治疗结果。
结果
该患者发生噬血细胞综合征，经6周期R-ECHOP化疗后达到完全缓解（CR），随后复发。经2周期PD-1抑制剂联合来那度胺治疗后，患者再次达到CR，同时白细胞介素（IL）-10表达水平降低。总共经过15周期化疗后，患者持续CR达24个月，IL-10水平维持在正常范围。
结论
PD-1抑制剂联合来那度胺方案可能是复发CD5 DLBCL的一种新的治疗方法。
Zotero 插件